Navigation Links
Drug Firms Sue British Regulator Over Alzheimer's Drugs

Two drug firms and a charity for people with Alzheimer's disease began a legal challenge Monday against the downgrading of three anti-dementia drugs by British regulators.

In 2001 the National Institute for Health and Clinical Excellence (NICE), which issues guidance on how medicines should be used in Britain, recommended three drugs from US drugs giant Pfizer and Japan's Eisai.

But last year it changed its advice for patients with moderate Alzheimer's after consultation, saying instead that the drugs should only be considered as options.

The drugs -- Aricept, the brand name for donepezil; Exelon, also known as rivastigmine, and Reminyl, or galantamine -- had not proven especially effective for people with mild Alzheimer's, NICE said.

Pfizer and Eisai were due to argue in a four-day hearing at London's High Court that the effectiveness appraisal process for the drugs was unfair and that NICE's decision was both procedurally flawed and irrational.

Lawyer David Pannick, representing Eisai, told judge Linda Dobbs that the change in NICE's guidance meant that 96,600 people per year with mild Alzheimer's would not now receive the drugs.

The Alzheimer's Society, which represents people with dementia, claimed ahead of the hearing that NICE had acknowledged the drugs worked but, at a cost of 2.50 pounds per person per day (3.71 euros, 4.99 dollars), decided they were not cost effective.

"These treatments have benefitted so many families already -- where is the justice in NICE's decision to snatch them away?" Neil Hunt, chief executive of the charity, said.

Andrew Dillon, chief executive of NICE, countered that its recommendations were not unfair and were developed after three years of analysis and discussion with doctors, patients and drug makers.

"For Alzheimer's disease, drugs are only part of the care that needs to be offered," he said.


'"/>




Page: 1 2

Related medicine news :

1. Firms Told To Employ Those With Aspergers Syndrome
2. Drug Firms To Produce Single Pill AIDS Treatment
3. 12 Chinese Firms Appeal Against Court Ruling On Viagra
4. Drug Firms Meet Annan, Pledge on AIDS Medicines
5. Drug Firms Competing to Produce Cheap and Effective bird flu vaccine
6. US, India Firms Develop New Cure for Black Fever
7. Chemical Firms are Secretly Paying Scientists
8. Supreme Court Seeks Replies From Cola Firms
9. A Non-profit Drug Firms Injection to Fight Kala Azar Included in WHOs Model List
10. Nexus Between Psychiatrists and Drug Firms Dangerous, Say Critics
11. Milk Firms in Philippines Violate Breastfeeding Code: WHO
Post Your Comments:
(Date:12/6/2009)... become a mainstay of multiple myeloma treatment may ... of patients who have received stem cell transplants ... clinical trial results to be presented by ... Society of Hematology,s (ASH) annual meeting on Sunday, ... Center, Room 243-245, 5:45 pm CT). , ...
(Date:12/6/2009)... Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today ... 2b 003-A1 study, known as the 003 trial, ... relapsed and refractory multiple myeloma patients. These data ... at the 51st annual meeting of the American ... in this trial is complete (n=269), and full ...
(Date:12/6/2009)... cooperation with the Greater VA Healthcare System in West Los Angeles, ... expected to soar to more than 5,000 veterans, active military personnel ... ... 6, 2009 -- Volunteer organizations and members of the community, in ... will once again create a holiday party. This year,s attendance is ...
(Date:12/5/2009)... CAPE TOWN, South Africa, December 5 The ... outskirts of Cape Town opened its doors,today (5 ... joined by,Western Cape Premier Helen Zille, 2010 FIFA ... Jordaan, South African Football Association,President Kirsten Nematandani and ...
(Date:12/5/2009)... Technology Center helps companies develop and test their cleaning processes. The ... variety of industries and solve problems for customers relating to cleaning ... ... 5, 2009 -- Midbrook, Inc , a Jackson, MI-based company, ...
Breaking Medicine News(10 mins):Health News:Bortezomib shows promise in reducing GVHD and reconstituting immune system in some patients 2Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 2Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 3Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 4Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 5Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 2Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 3Health News:Opening of First Football for Hope Centre Heralds a New Dawn for Khayelitsha 2Health News:Opening of First Football for Hope Centre Heralds a New Dawn for Khayelitsha 3Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 2Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 3
... have identified a subgroup of hard-to-treat breast cancers that ... in the treatment of breast tumors. They also have ... help identify patients most likely to benefit from cisplatin ... trial anticipated to begin at the MGH Gillette Center ...
... a dermatologist has a higher survival rate than by a ... to detect// the tumor in its early stages which can ... ,Individuals whose melanoma is diagnosed by a dermatologist may be ... years than those with melanoma diagnosed by a non-dermatologist, according ...
... from the researchers from Yale School of Medicine and ... first time found evidence of a// molecular mechanism that ... ,This discovery may help the development of ... and for cognitive changes in schizophrenia, bipolar disorder, or ...
... a Mediterranean country, is considered notoriously image-conscious. It may be ... clashing fiercely all the time. ,But the thirst ... ,Only that should explain why the Fist National Bank has ... ,Its website dubs the 'plastic surgery loans' as ...
... have found that the use of remote monitoring ... potential to significantly// improve clinical outcomes (mortality, morbidity ... remote monitoring (telephone support or telemonitoring) to electronically ... pressure, weight and ECG and oxygen details, to ...
... An initiative focused on motivating seniors and others with Medicare ... off by the U.S. Department of Health and Human Services ... The campaign is titled: A Healthier US Starts Here. ... the spring and summer, the Medicare Prevention tour bus will ...
Other Medicine News:Health News:Researchers Have Identified Subgroup Sensitive to the Drug Cisplatin 2Health News:Chances of Survival for Melanoma is High When Detected by Dermatologists 2Health News:New Light on Working of Brain Networks 2Health News:New Light on Working of Brain Networks 3Health News:Loans for Cosmetic Surgery in Lebanon 2Health News:Research Uncovers the Significant Benefits of Remote Monitoring 2Health News:Seniors Encouraged To Make Use Of Medicare’s Freebie 2
(Date:12/4/2009)... MARLTON, N.J., Dec. 4 Thermographic Diagnostic Imaging ... in Marlton, New Jersey continues to provide superior ... thyroid, dental, TMJ and sinus regions to assist ... these areas. ,, Thermography utilizes infrared imaging ...
(Date:12/4/2009)... Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced ... Principal investigators will discuss the data presentations surrounding ... at the 51st American Society of Hematology (ASH) Annual ... CT/10:00 a.m. ET on Monday, December 7, 2009. ...
(Date:12/4/2009)... (NYSE Amex: PIP ), a biodefense company developing ... the presentation of new data from the Company,s anthrax ... (rPA) based anthrax vaccine is structurally stable and potent ... including 55 degrees C. The data were presented ...
Breaking Medicine Technology:Discover Health Through Awareness 2Discover Health Through Awareness 3Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 3PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 4PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 5YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I II TRIAL OF JAK1 JAK2 INHIBITOR CYT387 ENROLLED BY CYTOPIA 14945 1YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I II TRIAL OF JAK1 JAK2 INHIBITOR CYT387 ENROLLED BY CYTOPIA 14945 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I II TRIAL OF JAK1 JAK2 INHIBITOR CYT387 ENROLLED BY CYTOPIA 14945 3YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I II TRIAL OF JAK1 JAK2 INHIBITOR CYT387 ENROLLED BY CYTOPIA 14945 4NuVasive To Present at the Piper Jaffray Health Care Conference and the J P Morgan SMid Cap Conference 6488 1NuVasive To Present at the Piper Jaffray Health Care Conference and the J P Morgan SMid Cap Conference 6488 2NuVasive To Present at the Piper Jaffray Health Care Conference and the J P Morgan SMid Cap Conference 6488 3West Announces Management Change 6485 1
... FREDERICK, Md., Jan. 7 ImQuest Life Sciences announced ... the Food and Drug Administration to initiate human clinical ... anticipates initiating their Phase 1 studies in the first ... inhibitor of HIV which primarily acts as a nonnucleoside ...
... a specialty,biopharmaceutical company focused on allergy and critical ... in 2008 with,its ToleroMune(R) anti-allergy technology, the company ... II clinical trial in cat allergy. The,study, which ... with confirmed,cat allergies, and all the participants have ...
Other Medicine Technology:ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 2Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 3
... The AB Holter, a ... system, provides sophisticated,ambulatory ECG analysis ... Windows environment.,Designed to use Windows ... the system allows,the option of ...
Olive Shaped Tip Cannula With Straight Shaft; in stainless steel....
... Designed to meet the ... of cardiology practices. The ... attenuation correction accessory features ... array that increases the ...
Sharp diamond shaped double blade in stainless steel....
Medicine Products: